The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy

被引:1
|
作者
Wang, Yongmei [1 ]
Li, Saisai [2 ]
Wang, Wenqin [3 ]
机构
[1] Qingdao Univ, Breast Dis Ctr, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[2] Qingdao Univ, Dept Hematol, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[3] Shandong Univ, Sch Life Sci, Qingdao, Shandong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
UPS; TIME; immune cells; immunotherapy; cancer; MHC CLASS-II; NF-KAPPA-B; DOWN-REGULATE PD-L1; T-CELLS; DENDRITIC CELLS; CANCER-CELLS; LIGASE KPC1; IMMUNOTHERAPY; EXPRESSION; COSTIMULATION;
D O I
10.3389/fimmu.2024.1436174
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The ubiquitin-proteasome system (UPS) plays a crucial role in modulating the proliferation, activation, and normal functioning of immune cells through the regulation of protein degradation and function. By influencing the expression of immune checkpoint-associated proteins, the UPS modulates T cell-mediated anti-tumor immune responses and can potentially facilitate the immune escape of tumor cells. Additionally, the UPS contributes to the remodeling of the tumor immunosuppressive microenvironment (TIME) by regulating B cells, dendritic cells (DCs), macrophages, and Treg cells. Targeting the UPS in conjunction with immune checkpoint-associated proteins, and combining these with other therapeutic approaches, may significantly enhance the efficacy of combination therapies and pave the way for novel cancer treatment strategies. In this review, we first summarize the composition and alterations of the TIME, with a particular emphasis on the role of the UPS in TIME and its interactions with various immune cell types. Finally, we explore the potential of combining UPS-targeted therapies with immunotherapy to substantially improve the effectiveness of immunotherapy and enhance patient survival outcomes.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Transcriptional control and the ubiquitin-proteasome system
    Tansey, WP
    Ejkova, E
    Kim, SY
    Herbst, A
    Muratani, M
    Salghetti, SE
    Tworkowski, KA
    FASEB JOURNAL, 2003, 17 (05): : A1184 - A1184
  • [42] The ubiquitin-proteasome system in colorectal cancer
    Voutsadakis, Ioannis A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2008, 1782 (12): : 800 - 808
  • [43] Bisretinoid Degradation and the Ubiquitin-Proteasome System
    Sparrow, Janet R.
    Zhou, Jilin
    Ghosh, Shanti Kaligotla
    Liu, Zhao
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 593 - 600
  • [44] The ubiquitin-proteasome system and neurodegenerative disorders
    Layfield, R
    Lowe, J
    Bedford, L
    ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 : 157 - 171
  • [45] Signaling through the ubiquitin-proteasome system
    Schulman, B.
    FEBS OPEN BIO, 2024, 14 : 5 - 6
  • [46] The ubiquitin-proteasome system: Focus on the heart
    Zolk, Oliver
    Schenke, Carolus
    Sarikas, Antonio
    CARDIOVASCULAR RESEARCH, 2006, 70 (03) : 410 - 421
  • [47] The ubiquitin-proteasome system in cardiac dysfunction
    Mearini, Giulia
    Schlossarek, Saskia
    Willis, Monte S.
    Carrier, Lucie
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2008, 1782 (12): : 749 - 763
  • [48] The ubiquitin-proteasome system in breast cancer
    Han, Dianwen
    Wang, Lijuan
    Jiang, Shan
    Yang, Qifeng
    TRENDS IN MOLECULAR MEDICINE, 2023, 29 (08) : 599 - 621
  • [49] Ubiquitin-proteasome system in diabetic retinopathy
    Svikle, Zane
    Peterfelde, Beate
    Sjakste, Nikolajs
    Baumane, Kristine
    Verkauskiene, Rasa
    Jeng, Chi-Juei
    Sokolovska, Jelizaveta
    PEERJ, 2022, 10
  • [50] Ubiquitin-Proteasome System and mitochondria - Reciprocity
    Livnat-Levanon, Nurit
    Glickman, Michael H.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2011, 1809 (02): : 80 - 87